- Home
- ABTS vs VYNE Comparison
ABTS vs VYNE Comparison
Compare ABTS & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABTS
- VYNE
- Stock Information
- Founded
- ABTS 2010
- VYNE 2003
- Country
- ABTS Hong Kong
- VYNE United States
- Employees
- ABTS N/A
- VYNE N/A
- Industry
- ABTS Computer Software: Programming Data Processing
- VYNE Biotechnology: Pharmaceutical Preparations
- Sector
- ABTS Technology
- VYNE Health Care
- Exchange
- ABTS Nasdaq
- VYNE Nasdaq
- Market Cap
- ABTS 8.9M
- VYNE 7.9M
- IPO Year
- ABTS N/A
- VYNE 2018
- Fundamental
- Price
- ABTS $3.48
- VYNE $0.30
- Analyst Decision
- ABTS
- VYNE Buy
- Analyst Count
- ABTS 0
- VYNE 2
- Target Price
- ABTS N/A
- VYNE $8.00
- AVG Volume (30 Days)
- ABTS 8.7K
- VYNE 1.9M
- Earning Date
- ABTS 08-13-2025
- VYNE 11-06-2025
- Dividend Yield
- ABTS N/A
- VYNE N/A
- EPS Growth
- ABTS N/A
- VYNE N/A
- EPS
- ABTS N/A
- VYNE N/A
- Revenue
- ABTS $7,037,156.00
- VYNE $476,000.00
- Revenue This Year
- ABTS N/A
- VYNE N/A
- Revenue Next Year
- ABTS N/A
- VYNE N/A
- P/E Ratio
- ABTS N/A
- VYNE N/A
- Revenue Growth
- ABTS 31.69
- VYNE N/A
- 52 Week Low
- ABTS $1.35
- VYNE $0.29
- 52 Week High
- ABTS $14.10
- VYNE $4.30
- Technical
- Relative Strength Index (RSI)
- ABTS 38.61
- VYNE 28.46
- Support Level
- ABTS $3.40
- VYNE $0.32
- Resistance Level
- ABTS $3.89
- VYNE $0.33
- Average True Range (ATR)
- ABTS 0.25
- VYNE 0.02
- MACD
- ABTS -0.03
- VYNE 0.03
- Stochastic Oscillator
- ABTS 9.54
- VYNE 11.44
About ABTS Abits Group Inc
Abits Group Inc is a digital data center operator with bitcoin self-mining operations. The group has its subsidiaries in USA, China, Canada and Hong Kong.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.